2011
Phase I/II trial of bevacizumab (B) and erlotinib (E) with induction (IND) and concurrent (CON) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic conformal radiotherapy (TCRT) in stage III non-small cell lung cancer (NSCLC).
Stinchcombe T, Socinski M, Moore D, Gettinger S, Decker R, Petty W, Blackstock A, Schwartz G, Lankford S, Morris D. Phase I/II trial of bevacizumab (B) and erlotinib (E) with induction (IND) and concurrent (CON) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic conformal radiotherapy (TCRT) in stage III non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2011, 29: 7016-7016. DOI: 10.1200/jco.2011.29.15_suppl.7016.Peer-Reviewed Original Research
2009
Incorporation of bevacizumab (B) and erlotinib (Er) with induction (Ind) and concurrent (Conc) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic radiotherapy in stage III non-small cell lung cancer (NSCLC)
Socinski M, Stinchcombe T, Halle J, Moore D, Petty W, Blackstock A, Gettinger S, Decker R, Khandani A, Morris D. Incorporation of bevacizumab (B) and erlotinib (Er) with induction (Ind) and concurrent (Conc) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic radiotherapy in stage III non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2009, 27: 7528-7528. DOI: 10.1200/jco.2009.27.15_suppl.7528.Peer-Reviewed Original ResearchNon-small cell lung cancerEpidermal growth factor receptorC therapyCohort IICohort IStage III non-small cell lung cancerVascular endothelial growth factor (VEGF) pathwayEndothelial growth factor pathwayPhase II regimenOverall survival rateCell lung cancerOverall response rateIncorporation of bevacizumabGrowth factor pathwaysConcurrent carboplatinGrowth factor receptorPrimary endpointPrincipal toxicityThoracic radiotherapyPS 0Lung cancerPrimary toxicityTreatment paradigmTumor volumeConformal radiotherapy